每经记者｜许立波 每经编辑｜魏官红 点评：最高人民法院驳回原告钟大放再审申请，意味着诺思格持续近两年的股权纠纷接近尘埃落定，尽 管公司称该诉讼案未对公司利润产生影响，但一定程度上对公司的外部声誉与投资者的信心造成了扰 动。 NO.3 华东医药：子公司依达拉奉片上市许可申请获受理 7月30日，华东医药公告称，公司全资子公司中美华东收到国家药品监督管理局签发的《受理通知 书》，由中美华东申报的依达拉奉片（研发代码：TTYP01）用于治疗急性缺血性脑卒中的上市许可申 请获得受理。依达拉奉是神经系统药物中的重磅品种，相对于院内给药14天的依达拉奉注射液，依达拉 奉口服片剂可以降低医药资源占用，适合患者自主长期给药。 点评：依达拉奉片如顺利获批上市，将进一步丰富华东医药心脑血管产品管线，在市场推广上有望与公 司现有产品形成有效协同。此外，尽管依达拉奉片为2.2类改良药，但剂型创新带来适应场景拓展，或 对原有注射剂市场形成部分替代，具备一定市场空间。 NO.4 南新制药：近期正筹划购买某一国内药品技术等资产组事项 丨 2025年7月31日 星期四 丨 NO.1 A股合成生物龙头华恒生物拟赴港上市 7月30日，华恒生物公告 ...

Group 1 - As of July 30, 2025, Huaheng Biological's stock price is 33.77 yuan, down 0.74 yuan or 2.14% from the previous trading day [1] - The trading volume on the same day was 54,947 hands, with a transaction amount of 188 million yuan [1] - Huaheng Biological operates in the chemical products industry, focusing on the research, production, and sales of amino acids and their derivatives, which are widely used in food, pharmaceuticals, and feed sectors [1] Group 2 - The company is planning to issue overseas shares and list on the Hong Kong Stock Exchange, with details yet to be determined [1] - This issuance will not change the company's controlling shareholder or actual controller [1] - As of July 30, 2025, the net outflow of main funds for Huaheng Biological was 6.0878 million yuan, accounting for 0.07% of the circulating market value [1]

证券代码：688639 证券简称：华恒生物 公告编号：2025-030 安徽华恒生物科技股份有限公司 关于筹划公司在香港联合交易所有限公司上市的 科创板股票上市规则》 《境内企业境外发行证券和上市管理试行办法》 《香港联合 交易所有限公司证券上市规则》等相关规定，待确定具体方案后，本次 H 股上市 工作尚需提交公司董事会和股东大会审议，并经中国证券监督管理委员会备案和 香港联交所等监管机构审核。 本次 H 股上市能否通过审议、备案和审核程序并最终实施具有较大不确定性。 公司将依据相关法律法规的规定，根据本次 H 股上市的后续进展情况及时履行信 息披露义务。本次 H 股上市尚存在较大不确定性，敬请广大投资者理性投资，注 意投资风险。 安徽华恒生物科技股份有限公司（以下简称"公司"）为深入推进公司全球 化发展战略，提升品牌影响力与核心竞争力，巩固行业领先地位，充分借助国际 资本市场的资源与机制优势，优化资本结构，拓宽多元融资渠道，全面提升公司 治理水平和综合实力，正在筹划发行境外股份（H 股）并在香港联合交易所有限 公司（以下简称"香港联交所"）上市事宜（以下简称"本次 H 股上市"）。公司 正与相关中介机构就本 ...

今日焦点 宁德时代：上半年实现净利润305亿元同比增长33.02% 宁德时代公告，上半年实现收入1789亿元，同比增加7.27%；净利润305亿元，同比增长33.02%。报告 期内，本集团实现毛利448亿元，相比2024年同期增加14.45%；综合毛利率为25.02%，相比2024年同期 的23.45%上升1.57个百分点。 上纬新材：多次触及股票交易异常波动和严重异常波动情形明起停牌核查 上纬新材公告称，公司股票自2025年7月9日至7月30日期间多次触及股票交易异常波动及严重异常波动 情形。公司将于7月31日开市起停牌，预计停牌时间不超过3个交易日。公司基本面未发生重大变化，但 股票交易价格已严重脱离基本面，投资者参与交易可能面临较大市场风险。此外，公司股票价格涨幅显 著高于同期相关指数涨幅，换手率显著高于前期水平，市盈率显著高于行业平均水平。公司主营业务和 生产经营未发生重大变化，收购方未来十二个月内不存在资产重组计划，但控制权变更事项仍存在重大 不确定性风险。 金橙子：筹划购买萨米特光电55%股权，股票停牌 金橙子公告称，公司正在筹划以发行股份及支付现金的方式购买长春萨米特光电科技有限公司55%的股 ...

（原标题：7月30日重要资讯一览） 重要的消息有哪些 1．中共中央政治局7月30日召开会议，会议指出，要持续防范化解重点领域风险。落实好中央城市工作会议精神，高质量开展城市更新。积极稳 妥化解地方政府债务风险，严禁新增隐性债务，有力有序有效推进地方融资平台出清。增强国内资本市场的吸引力和包容性，巩固资本市场回稳 向好势头。 2．财政部社会保障司司长郭阳7月30日在国新办新闻发布会上表示，中央财政将设立共同财政事权转移支付项目"育儿补贴补助资金"，今年初步 安排预算900亿元左右。对于发放国家基础标准补贴所需资金，中央财政按照一定比例对地方予以补助，中央财政总体承担90%。 3．7月30日，外交部发言人郭嘉昆主持例行记者会。在回答有关中美经贸会谈的问题时，郭嘉昆表示，关于此次中美经贸会谈的情况，中方已经 发布了消息。我们希望美方同中方一道，按照两国元首通话达成的重要共识，发挥好中美经贸磋商机制的作用，在平等、尊重、互惠基础上，通 过对话沟通，增进共识、减少误解、加强合作，争取更多双赢成果，共同推动中美关系健康稳定可持续发展。 4．国家发改委向社会公开征求《政府投资基金布局规划和投向工作指引》和《加强政府投资基金 ...

Important Announcements - Company Shouwei New Materials will suspend trading for inspection on July 31, 2025, due to abnormal stock price fluctuations from July 9 to July 30, 2025 [2] - Company XGIMI Technology expects a net profit attributable to shareholders of 88.66 million yuan for the first half of the year, a year-on-year increase of 2062.33% [4] - Company Yuntian Lifei has submitted an application for H-share issuance and listing [5] - Company Huaheng Biological is planning to issue H-shares and list on the Hong Kong Stock Exchange [6] - Company Hehua Co., Ltd. is planning a change in control, leading to a suspension of trading [10] Financial Performance - Company Dingtong Technology reported a net profit of 115 million yuan for the first half of the year, a year-on-year increase of 134.06%, with a proposed cash dividend of 2 yuan per 10 shares [7] - Company Jinhai Biological achieved a net profit of 138 million yuan in the first half of the year, a year-on-year increase of 51.52% [13] - Company Hisense Home Appliances reported a net profit of 2.077 billion yuan for the first half of the year, a year-on-year increase of 3.01% [14] Corporate Actions - Company Nanxin Pharmaceutical is planning to acquire a domestic pharmaceutical technology asset group, but there is significant uncertainty regarding the completion of this acquisition [3] - Company Jinchengzi is planning to acquire 55% of the shares of Changchun Samit Optoelectronics Technology Co., Ltd., leading to a suspension of trading [9] - Company San Chao New Materials is also planning a change in control, resulting in a trading suspension [11] Project Investments - Company Changjiang Electric Power plans to invest approximately 26.6 billion yuan in the construction of the Gezhouba Navigation Capacity Expansion Project [8]

Group 1: Company Announcements - Upwind New Materials will suspend trading for stock review starting July 31, 2025, due to abnormal price fluctuations from July 9 to July 30, 2025 [2] - XGIMI Technology expects a net profit attributable to shareholders of 88.66 million yuan for the first half of 2025, a year-on-year increase of 2062.33% [4] - CloudWalk Technology has submitted an application for H-share issuance and listing on the Hong Kong Stock Exchange [5] - Huaheng Biological is planning to issue H-shares and list on the Hong Kong Stock Exchange [6] - Hehua Co., Ltd. is undergoing a control change process, leading to a stock suspension starting July 31, 2025 [9] Group 2: Financial Performance - DingTong Technology reported a net profit of 115 million yuan for the first half of 2025, a year-on-year increase of 134.06%, with a proposed cash dividend of 2 yuan per 10 shares [7] - Jinhe Biological achieved a net profit of 138 million yuan in the first half of 2025, a year-on-year increase of 51.52% [12] - Hisense Home Appliances reported a net profit of 2.077 billion yuan for the first half of 2025, a year-on-year increase of 3.01% [13] Group 3: Corporate Developments - Nanxin Pharmaceutical is planning to acquire a domestic pharmaceutical technology asset group, but there is significant uncertainty regarding the completion of this acquisition [3] - Jinchengzi is planning to acquire 55% of the equity of Changchun Samit Optoelectronics Technology Co., Ltd., leading to a stock suspension starting July 31, 2025 [8] - SanChao New Materials is also planning a control change, resulting in a stock suspension starting July 31, 2025 [10] Group 4: Industry Developments - Changjiang Electric Power plans to invest approximately 26.6 billion yuan in the construction of the Gezhouba Navigation Capacity Expansion Project, with a total construction period of 91 months [8] - Yonghui Supermarket intends to raise no more than 3.992 billion yuan through a private placement to upgrade stores and logistics [8]

北京商报讯（记者丁宁）7月30日晚间，华恒生物（688639）发布公告称，公司为深入推进公司全球化 发展战略，提升品牌影响力与核心竞争力，巩固行业领先地位，充分借助国际资本市场的资源与机制优 势，优化资本结构，拓宽多元融资渠道，全面提升公司治理水平和综合实力，正在筹划发行境外股份 （H股）并在香港联交所上市事宜。 （文章来源：北京商报） ...

Group 1 - Company Shenzhou New Materials has experienced multiple instances of abnormal stock trading fluctuations and will be suspended from trading starting July 31, 2025, for up to three trading days [1] - The stock price of Shenzhou New Materials has increased over 1288% this year, making it the first tenfold stock of 2025 [1] - Company Yangtze Power plans to invest approximately 26.6 billion yuan in the construction of the Gezhouba shipping capacity expansion project, with funding sourced from its own funds [2] - Yonghui Supermarket intends to raise no more than 3.992 billion yuan through a private placement of A-shares for store upgrades and logistics improvements [3] Group 2 - Chipsea Technology is planning to issue H-shares and apply for listing on the Hong Kong Stock Exchange to enhance its international strategy and competitiveness [4] - Zhongwang Software is facing a copyright infringement lawsuit from Autodesk in a California federal court, with the amount in dispute yet to be determined [5] - Jinchengzi is planning to acquire 55% of the equity of Changchun Samit Optoelectronics Technology Co., Ltd., and will suspend trading starting July 31, 2025, for up to ten trading days [6] - Nanxin Pharmaceutical is in the process of planning the acquisition of a domestic pharmaceutical technology asset group, with significant uncertainty regarding whether it constitutes a major asset restructuring [7] Group 3 - Huaheng Biological is preparing to issue H-shares and list on the Hong Kong Stock Exchange to advance its global strategy [9] - Sanchao New Materials is planning a change in company control and will suspend trading starting July 31, 2025, for up to two trading days [10] - Digital Certification's controlling shareholder will change to Beijing Data Group following a transfer of state-owned shares [11] - Hongxiang Co., Ltd.'s actual controller has been placed under residential surveillance, but this will not affect the company's normal operations [12]

本次 H 股上市能否通过审议、备案和审核程序并最终实施具有较大不确定性。 公司将依据相关法律法规的规定，根据本次 H 股上市的后续进展情况及时履行信 息披露义务。本次 H 股上市尚存在较大不确定性，敬请广大投资者理性投资，注 意投资风险。 特此公告。 提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 安徽华恒生物科技股份有限公司（以下简称"公司"）为深入推进公司全球 化发展战略，提升品牌影响力与核心竞争力，巩固行业领先地位，充分借助国际 资本市场的资源与机制优势，优化资本结构，拓宽多元融资渠道，全面提升公司 治理水平和综合实力，正在筹划发行境外股份（H 股）并在香港联合交易所有限 公司（以下简称"香港联交所"）上市事宜（以下简称"本次 H 股上市"）。公司 正与相关中介机构就本次 H 股上市的具体推进工作进行商讨，相关细节尚未确定， 本次 H 股上市不会导致公司控股股东和实际控制人发生变化。 根据《中华人民共和国公司法》《中华人民共和国证券法》《上海证券交易所 科创板股票上市规则》《境内企业境外发行证券和上市管理 ...